Skip to Content

Jennison Associates LLC has purchased shares of Bio-Rad Laboratories, Inc. (NYSE:BIO).

Jennison Associates LLC has purchased shares of Bio-Rad Laboratories, Inc. (NYSE:BIO).

The most recent Form 13F filing that Jennison Associates LLC had with the Securities and Exchange Commission revealed that the company increased its holdings in Bio-Rad Laboratories, Inc. (NYSE: BIO) during the third quarter by 1.5 percentage points (SEC). The fund has a total holding of 66,234 shares of the stock held by the medical research company after purchasing an additional 1,399 shares during the quarter to bring the total number of shares it owns to a total of 66,234. At the close of the most recent fiscal quarter, Jennison Associates LLC owned approximately 0.22% of Bio-Rad Laboratories’ shares, with a total market value of $27,629,000.

Over the past few years, several other notable investors have cut back on the amount of stock they own in the company. Veritas Asset Management LLP increased its total investment in Bio-Rad Laboratories to approximately $379,547,000 during the second quarter by purchasing a new holding in the company. This brought the total value of the company’s holdings to approximately $379,547,000. During the second quarter, a new position in Bio-Rad Laboratories cost AustralianSuper Pty Ltd approximately $191,846,000 to fill. The company fronted the money for this investment itself. During the second quarter, Artemis Investment Management LLP successfully increased the percentage of Bio-Rad Laboratories in which it holds a stake by 97.6%. After making an additional purchase of 96,691 shares during the relevant period, Artemis Investment Management LLP now has a total of 195,787 shares of stock in the medical research company. The stock has a value of $97,034,000, and Artemis Investment Management LLP owns these shares. Millennium Management LLC was successful in adding 19.3% more shares of Bio-Rad Laboratories to its portfolio over the second quarter. Millennium Management LLC now holds 379,329 shares of the medical research company’s stock after purchasing an additional 61,424 shares during the most recent period. The stock is currently valued at $187,768,000, and Millennium Management LLC’s holdings are worth $187,768,000.

Last but not least, during the first three months of this year, Prudential Financial Inc. increased the proportion of Bio-Rad Laboratories owned by an additional 181.0 percent. Prudential Financial Inc. now has a total of 85,053 stock held by the medical research company. This was accomplished by purchasing an additional 54,789 shares during the most recent fiscal quarter. These shares have a value equivalent to $47,905,000 as a whole. Shares of the company are currently held by various types of institutional investors, including hedge funds, to the extent of 64.35 percent.

BIO began trading at $455.20 on Tuesday. The company currently has a simple moving average of $416.86 for the past 50 days, and the company’s simple moving average for the past 200 days is $450.30. The debt-to-equity ratio comes in at 0.14, the quick ratio comes in at 4.30, the current ratio comes in at 5.50, and the quick ratio comes in at 4.30. During the past year, the price of a share of Bio-Rad Laboratories, Inc. has fluctuated between $344.63 and $670.61, with the average price being $670.61. The company’s market capitalization is $13.58 billion, the price-to-earnings ratio for the stock is -2.26, and the company has a beta value of 0.91.

Thursday, October 27, saw the release of the results of the most recent quarterly financial report that Bio-Rad Laboratories (NYSE: BIO) had produced. The medical research company reported quarterly earnings per share (EPS) of $2.60, which was $0.01 higher than the consensus prediction of $2.59. The earnings were reported for the company’s most recent quarter. Although Bio-Rad Laboratories had a positive return on equity of 4.13%, the company’s net margin was a negative 215.16%. The actual sales for the company during the quarter came in at $680.10 million, which is significantly lower than the consensus projection of $685.50 million. During the previous year, the corporation generated $3.71 per share earnings for each shareholder. The company’s quarterly sales dropped by 9.0% when measured against


Leave a comment

Your email address will not be published. Required fields are marked *